

openMetaAnalysis: PICO Table

Trial	Patients	Intervention	Comparison	Outcome
Daum, 2017 NEJM PMID: 28657870 NCT: 00730028	<ul style="list-style-type: none"> • 786 subjects (505 adults, 281 children) • Mean age 25.5 years • Induration 2.2 cm • 49.4% MRSA 	TMP-SMX <ul style="list-style-type: none"> • 160/800 mg twice daily • 10 days Clindamycin <ul style="list-style-type: none"> • 300 mg three times daily 	Placebo	Primary: <ul style="list-style-type: none"> • Clinical Cure by Day 7-10 Secondary: <ul style="list-style-type: none"> • Cure rates at 1-month follow-up visits, percentage of MSSA/MSSA
Talan, 2016 NEJM PMID: 26962903 NCT: 00729937	<ul style="list-style-type: none"> • 1265 subjects • Mean age 35 years • Induration 2.2 cm • 43% MRSA 	TMP-SMX <ul style="list-style-type: none"> • 320/1600 mg twice daily • 7 days 	Placebo	Primary: <ul style="list-style-type: none"> • Clinical Cure (Assessed 7-14 days after treatment) Secondary: <ul style="list-style-type: none"> • Recurrence at same or different site
Chen. 2011 Pediatrics PMID 21339275 NCT00352612	<ul style="list-style-type: none"> • 200 subjects • Mean age NA • Induration 3.5 cm • 69% MRSA 	Cephalexin <ul style="list-style-type: none"> • 40 mg/kg per day divided three times daily • 7 days Clindamycin <ul style="list-style-type: none"> • 20 mg/kg per day divided three times daily • 7 days 	NA	Primary: <ul style="list-style-type: none"> • Clinical improvement at 48 to 72 hours Secondary: <ul style="list-style-type: none"> • Resolution at 7 days
Schmitz, 2010	• 212 subjects	TMP-SMX	Placebo	Primary:

Ann Emerg Med PMID: 20346539 NCT: 00822692 NCT: 00973765	<ul style="list-style-type: none"> • Mean age 28 years • Induration 4.8 cm • 53% MRSA 	<ul style="list-style-type: none"> • 160 mg/800 mg twice daily • 7 days 		<ul style="list-style-type: none"> • Treatment Failure within 7 Days Secondary: <ul style="list-style-type: none"> • New Lesion formation within 30 days
Duong, 2009 Ann Emerg Med PMID: 19409657 NCT: 00679302	<ul style="list-style-type: none"> • 161 subjects • Mean age 4 years • Induration 3.6 cm • 80% MRSA 	TMP-SMX <ul style="list-style-type: none"> • 10-12 mg trimethoprim/kg/day twice daily up to 160 mg trimethoprim • 10 days 	Placebo	Primary: <ul style="list-style-type: none"> • Clinical Resolution Secondary: <ul style="list-style-type: none"> • New lesion at a different site on Day 10, New lesion at 3 month telephone follow up
Rajendran, 2007 Antimicrob Agents Chemother PMID: 17846141 NCT: 00187759	<ul style="list-style-type: none"> • 166 randomized subjects • Mean age 43 years • Induration 4.9 cm • 87% MRSA 	Cephalexin <ul style="list-style-type: none"> • 500 mg four times daily • 7 days 	Placebo	Primary: <ul style="list-style-type: none"> • Clinical Cure or Failure after 7 days